Cleerly, Inc.
The overall objective of CONFIRM2 is to perform the largest cardiovascular phenotype outcomes study ever.
CONFIRM2 is a retrospective and prospective, open-label, international, multicenter observational registry designed to evaluate associations between CCTA imaging findings and clinical presentation (cross-sectional) and their ability to predict mortality and major adverse cardiac events (longitudinal) in patients with chronic CAD.
Inclusion Criteria: * Age \>18 years * Undergoing clinically indicated CCTA with \>64-detector row CT * Signed informed consent, including of release of medical information, long term follow-up and Health Insurance Portability and Accountability Act (HIPAA) documentation Exclusion Criteria: * Individuals unable to provide informed consent * Non-cardiac illness with life expectancy \< 2 years * Pregnancy
Verify or correct the compensation shown for this listing.